Not Yet RecruitingNot Applicable

A Real World Study of Elranatamab in Patients With RR Multiple Myeloma in Taiwan

Taiwan30 participantsStarted 2026-04-30

Plain-language summary

The purpose of this study is to evaluate: * What is the real-world effectiveness of elranatamab in patients with relapsed and/or refractory multiple myeloma (RRMM) in Taiwan? * What are the baseline and clinical characteristics of RRMM patients who have received eltanatamab in Taiwan? * What are the treatment patterns of RRMM patients receiving elranatamab in the real-world setting in Taiwan?

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Patients age ≥ 18 years at the initiation of elranatamab
. Patients who have received at least one dose of elranatamab in consistent with the approved label in Taiwan.
. Evidence of a personally signed and dated informed consent document (ICD) indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study. The ICD waiver is acceptable for patient who was ceased before recruitment.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

rwTTR (real-world time to response)

Timeframe: At 1 month, 3 months, 6 months, 9 months, 12 months, and 18 months following initiation of elranatamab treatment (index date.)

rwORR (real-world overall response rate)

Timeframe: At 1 month, 3 months, 6 months, 9 months, 12 months, and 18 months following initiation of elranatamab treatment (index date.)

rwDOR (real-world duration of response）

Timeframe: From first response until 18 months

rwPFS (real-world progression-free survival)

Timeframe: From initiation of elranatamab treatment (index date) until 18 months

rwOS (real world overall survival)

Timeframe: From initiation of elranatamab treatment (index date) until 18 months

rwTTNT (real world time to next treatment)

Timeframe: From initiation of elranatamab treatment (index date) until 18 months

Trial details

NCT IDNCT07391761

SponsorPfizer

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2028-01-31

Contact for this trial

Pfizer CT.gov Call Center

1-800-718-1021 ClinicalTrials.gov_Inquiries@pfizer.com

View on ClinicalTrials.gov More Refractory Multiple Myeloma (RRMM) trials

Plain-language summary

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Patients age ≥ 18 years at the initiation of elranatamab
. Patients who have received at least one dose of elranatamab in consistent with the approved label in Taiwan.
. Evidence of a personally signed and dated informed consent document (ICD) indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study. The ICD waiver is acceptable for patient who was ceased before recruitment.

What they're measuring

rwTTR (real-world time to response)

Timeframe: At 1 month, 3 months, 6 months, 9 months, 12 months, and 18 months following initiation of elranatamab treatment (index date.)

rwORR (real-world overall response rate)

Timeframe: At 1 month, 3 months, 6 months, 9 months, 12 months, and 18 months following initiation of elranatamab treatment (index date.)

rwDOR (real-world duration of response）

Timeframe: From first response until 18 months

rwPFS (real-world progression-free survival)

Timeframe: From initiation of elranatamab treatment (index date) until 18 months

rwOS (real world overall survival)

Timeframe: From initiation of elranatamab treatment (index date) until 18 months

rwTTNT (real world time to next treatment)

Timeframe: From initiation of elranatamab treatment (index date) until 18 months